Evidence map›Paper›PMID 42698006›Full record

ArticleClinical pharmacology and therapeutics2026

Physiologically Based Pharmacokinetic Modeling to Assess Transporter-Mediated Drug-Drug Interactions in Support of Labeling Recommendations for Zavegepant Nasal Spray.

Alice Ke, Ernesto Callegari, Manthena V S Varma, Mayur K Ladumor, Chieko Muto, Richard J Bertz, Hannah M Jones, Vaishali Sahasrabudhe, Jing Liu

Abstract read
In one paragraph

Article in Clinical pharmacology and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Alice KeCertara USA, Radnor, Pennsylvania, USA.
Ernesto CallegariPfizer Inc, Groton, Connecticut, USA.
Manthena V S VarmaPfizer Inc, Groton, Connecticut, USA.ORCID https://orcid.org/0000-0002-9541-6329
Mayur K LadumorPfizer Inc, Collegeville, Pennsylvania, USA.
Chieko MutoPfizer R&D Japan, Tokyo, Japan.
Richard J BertzBiohaven Pharmaceuticals, New Haven, Connecticut, USA.
Hannah M JonesCertara USA, Radnor, Pennsylvania, USA.
Vaishali SahasrabudhePfizer Inc, Groton, Connecticut, USA.ORCID https://orcid.org/0009-0007-2592-6490
Jing LiuPfizer Inc, Groton, Connecticut, USA.ORCID https://orcid.org/0000-0001-9481-5961

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Zavegepant nasal spray, a calcitonin gene-related peptide receptor antagonist indicated for acute treatment of migraine with or without aura in adults, is a substrate for organic anion transporting polypeptide 1B3 (OATP1B3), Na

Identifiers

PMID42698006
PMCPMC13545016

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.